Fundamental and clinical studies on cefuroxime axetil in oral infections.
スポンサーリンク
概要
- 論文の詳細を見る
Fundamental and clinical studies were carried out for evaluating the usefulness of Cefuroxime axetil (CXM-AX) in the treatment of periodonitis, pericoronitis or osteitis of the jaw. The results are summarized below.<BR>1. At 60-120 minutes after oral administration of CXM-AX 250mg, CXM levels in the cyst, the gum and the alveolar bone tissues were 1.64μg/g (mean of 8 samples), 1.24μg/g (1 sample) and 0.24μg/g (1 sample), respectively, and ratio of tissue levels to serum levels were 66.4, 58.2 and 8.6%, respectively. At 90-135 minutes after the administration of CXM-AX 500mg, mean CXM levels in the cyst, the gum and the alveolar bone were 1.07μg/g (3 samples), 1.63μg/g (3 samples) and 0.7μg/g (2 samples), respectively, and ratio of tissue levels to serum levels were 22.2, 26.5 and 29.1%, respectively.<BR>2. In the clinical evaluation, 28 patients receved orally either 250mg or 500mg of CXM-AX three times daily. Both in assessment based on scores and in physician's assessment, the efficacy rate in the total cases was 89.3%. The efficacy rates were 86.4% in 22 cases in the 750mg administration group, and 100%, in 6 cases in the 1500mg administration group.<BR>3. Bacteriological examination was performed in 17 strains isolated from 11 out of 28 patients. CXM, at the concentration of 0.78μg/ml or lower, inhibited the growth of every isolate.<BR>4. As for adverse events, only mild nausea and vomitting were observed in one patient out of the 28 (3.6%) .<BR>From the above, CXM-AX is considered to be highly useful in the treatment of oral surgical infections.
- 日本歯科薬物療法学会の論文
日本歯科薬物療法学会 | 論文
- カンジダのバイオフィルム産生性に対する抗真菌薬の効果
- 当院における全身麻酔下手術中に使用された抗菌薬の15年間(1992-2006年)の推移
- 「顎骨骨髄炎に対する抗菌薬の効果判定基準」の解析結果
- 植物精油の口腔微生物に対する抗菌性およびバイオフィルム形成抑制効果の検討
- ニフェジピン歯肉増殖症患者の線維芽細胞に対する18α-グリチルレチン酸のアポトーシス誘導効果